Leukocare AG announced the signing of a cooperation agreement with Sanofi Pasteur, the vaccines division of Sanofi.
JHP Pharmaceuticals has entered into an agreement with an undisclosed biotech company to produce clinical trial batches of an innovative drug used in the treatment of heart failure.
Anavex Life Sciences Corp. conducted a study entitled, “The novel aminotetrahydrofuran derivative Anavex 2-73 attenuated GSK-3beta and Tau hyperphosphorylation in a nontransgenic Alzheimer’s disease model in mice.”
Food-poisoning has been revealed as a new target for nitric oxide in studies of how it inhibits the growth of Salmonella.
A genome-wide association study has found two tiny genetic variations that can predict which patients with Hodgkin's lymphoma are most likely to develop radiation-induced second cancers years after treatment.
Sigma Life Science announced the expansion of its CompoZr Oncology Disease Model portfolio with the release of the first in its collection of breast cancer-specific knock-out and knock-in cell lines for drug discovery and research.
Optibrium has launched a new version of StarVue, its innovative free desktop application that enables scientists to quickly and conveniently view sets of compound structures and related data.
Agilent Technologies Inc. and A*STAR’s Experimental Therapeutics Centre launched a drug-screening platform within ETC’s Singapore Screening Centre. A*Star selected Agilent to provide a full spectrum of automation technologies to biomedical researchers.
Those who help foot the bills for prescription drugs - patients, taxpayers, employers and some labor unions - won't be the only ones to benefit as dozens of popular brand-name pills get generic competition over the next several years.
Valeant Pharmaceuticals International Inc. said that Canadian regulators have approved its insomnia treatment Sublinox, and it expects to launch the product in the fourth quarter in Canada.
Baxter International Inc. announced that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% for patients with primary immunodeficiency.
A new study shows it is possible, using a targeted antisense therapy called AVI-4658, to restore expression of a key protein that is lacking in patients with the seriously debilitating condition Duchenne muscular dystrophy.
Healthcare giant Johnson & Johnson plans to meet with U.S. regulators after they refused to approve a new use for the company's immune disorder drug, Simponi.
The cost of prescription medicines used by millions of people every day is about to plummet. The next 14 months will bring generic versions of seven of the world's 20 best-selling drugs.
Sherpa Clinical Packaging, a provider of clinical trial material management services, opened its newly constructed CGMP production facility co-located adjacent to the Althea Technologies campus; Sherpa and Althea entered into a co-marketing agreement in March 2011.